3 Must-Buy Stocks Right Now—Top Analysts’ Picks for June 26, 2025

Wall Street's sharpest minds are doubling down on these high-conviction plays—just as retail investors start panic-selling (again).

1. The AI Powerhouse Printing Money While Competitors Burn Cash

One Nasdaq giant's proprietary chips are eating Nvidia's lunch—and their 78% profit margins prove it.

2. The Obscure Energy Play Quietly Dominating Carbon Credits

This Texas-based firm turned 'boring' infrastructure into a $3B arbitrage machine against EU climate policies.

3. The Pharma Stock That Short Sellers Can't Kill

Despite 12 failed short reports, this biotech keeps hitting trial endpoints—and just secured FDA fast-track.

Funny how these 'top picks' always align with bulge bracket banking fees—but the charts don't lie. Time to position before the next FOMC meeting sends hedgies scrambling.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts. 

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.

(LLY) – Eli Lilly is a U.S.-based pharmaceutical company focused on developing and marketing medicines for conditions like diabetes, cancer, and neurological disorders. Yesterday, TD Cowen analyst Steve Scala maintained a Buy rating on the stock with a price target of $1,190 per share. Interestingly, nine out of the 10 Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 22.96%. 

(BBIO) – This is a U.S. biotech company that develops drugs for rare genetic diseases and certain cancers. Yesterday, Bank of America Securities analyst Jason Zemansky maintained a Buy rating on the stock and increased the price target from $50 to $54 per share. In the last three months, all six Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 44.95%.

(BEAM)– This is a biotech company focused on pioneering the use of “base editing” to develop potential one-time treatments for serious genetic diseases. Yesterday, J.P. Morgan analyst Eric Joseph maintained a Buy rating on the stock and increased the price target from $25.61 to $48 per share. In the last three months, all four Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 189.4%.

Who Are the Top Analysts? 

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time. 

See real-time analyst rankings and learn more about the performance of Top Analysts on TipRanks’ Top Wall Street Analysts page. 

Disclosure